SPC
VRTX icon

Spirepoint Private Client’s Vertex Pharmaceuticals VRTX Stock Holding History

Spirepoint Private Client’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-502
Closed -$228K – 341
2025
Q4 		$228K Buy
+502
New +$216K 0.02% 285

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Spirepoint Private Client's VRTX Position: Q1 2026 in Review

Spirepoint Private Client sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 502 shares — an estimated $228K sold.

Spirepoint Private Client first reported a position in VRTX in Q4 2025 and held it in 1 quarter. The position peaked at $228K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Spirepoint Private Client reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Spirepoint Private Client sold 502 Vertex Pharmaceuticals shares in Q1 2026, an estimated $228K.
  • Spirepoint Private Client first reported a position in Vertex Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Spirepoint Private Client's Vertex Pharmaceuticals position peaked at $228K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Spirepoint Private Client's 13F filing for Q1 2026, filed 22 Apr 2026.